Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (593)	5/29/2002 9:56:17 AM
From: nigel bates	Read Replies (1) \| Respond to of 2240

Is that from this ? ANNANDALE, N.J., Sept. 16 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it has entered into an antibody development agreement with Medac Hamburg, Germany, a privately held company. Under this research collaboration and license agreement, Medarex will use its patented technology to produce a new Bispecific antibody to treat Hodgkin's Lymphoma. Medarex will employ its HuMAb-Mouse(TM) technology to generate a fully human monoclonal antibody to CD30, a potential cancer antigen for which Medac claims proprietary rights. The new agreement is Medarex's eighth corporate partnership based on its fully human monoclonal antibody technology. Medarex has ongoing partnerships for the HuMAb-Mouse technology with numerous global pharmaceutical and biotechnology companies, including Bristol Myers Squibb, Centocor, Inc., and Schering AG, Germany. Potential revenues from all eight collaborations including licensing fees, milestone payments and manufacturing revenues exceed $130 million plus royalties on commercial sales... And was the SGEN MAb from ther collaboration with MEDX ? BOTHELL, Wash., Mar 21, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of its first phase I clinical trial with the therapeutic monoclonal antibody SGN-30 for the treatment of hematologic malignancies. The single agent study is designed as a rapid dose escalation to assess the safety and pharmacokinetic profile of SGN-30 in patients with hematologic malignancies such as Hodgkin's disease, anaplastic large cell lymphoma and certain other lymphomas. The trial is being conducted at the Siteman Cancer Center at Washington University in St. Louis, Missouri, MD Anderson Cancer Center in Houston, Texas, and Norris Cancer Center at the University of Southern California in Los Angeles, California. "SGN-30 is a monoclonal antibody that targets CD30, a cell surface receptor expressed in high density on a variety of hematologic malignancies," stated Clay B. Siegall, Ph.D., President and Chief Scientific Officer at Seattle Genetics. "SGN-30 is unique in that it can directly kill Hodgkin's disease cells, where other antibodies targeting CD30 have not demonstrated such activity."...